Qurient Co., Ltd.

NEW YORK and MUMBAI (January 30, 2026)—TB Alliance, a nonprofit drug developer, and Lupin Limited (Lupin), a global pharma major, today announced a global collaboration to advance the clinical development and commercialization of the investigational drug telacebec (formerly known as Q203) for the treatment of tuberculosis (TB), leprosy, and Buruli ulcer. Under the collaboration, TB Alliance and Lupin will work together to support the continued clinical development of telacebec and prepare for its potential future commercialization, with the shared goal of improving treatment options for people affected by these neglected diseases. TB Alliance will continue to lead development activities, while Lupin will bring its global manufacturing, regulatory, and supply expertise to help ensure broad access to telacebec. “Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said Mel Spigelman, MD, President and CEO, TB Alliance. “By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls (CMC) and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.” “Our collaboration with TB Alliance underscores Lupin’s dedication to addressing unmet medical needs of the patients affected by TB, leprosy, and Buruli ulcer. By leveraging our manufacturing and distribution capabilities together with TB Alliance’s leadership in drug development, we aim to deliver Telacebec to those in need and positively contribute to the global efforts against these diseases,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of API Plus SBU, Lupin. Telacebec is a novel, first-in-class compound with potent activity against multiple mycobacterial pathogens. TB Alliance already has clinical development underway to evaluate the safety and efficacy of telacebec for Buruli ulcer, including an active Phase 2 clinical trial in Australia. In parallel, TB Alliance is advancing the TEBULA program, supported by the European & Developing Countries Clinical Trials Partnership (EDCTP), to accelerate development of telacebec for both Buruli ulcer and leprosy. These trials and this partnership underscore TB Alliance’s commitment to identifying and advancing new treatment options with the potential to help bring an end to neglected diseases. Telacebec has the potential to offer a novel therapeutic approach across multiple mycobacterial diseases, helping to simplify treatment and improve outcomes for people impacted by these neglected diseases worldwide. TB, leprosy, and Buruli ulcer are all caused by mycobacterial infections and disproportionately affect underserved and marginalized populations. TB remains one of the world’s leading infectious disease killers, claiming more than a million lives each year. Leprosy, a chronic infectious disease, continues to cause disability and stigma for hundreds of thousands of people globally. Buruli ulcer, a neglected tropical disease, can lead to severe skin and soft tissue damage if not treated early and remains poorly served by current therapies. Together, these diseases underscore the urgent need for new, effective, and accessible treatment options. About Telacebec Telacebec (Q203) is a novel, first-in-class investigational compound being developed by TB Alliance for the treatment of multiple mycobacterial diseases, including tuberculosis, leprosy, and Buruli ulcer. TB Alliance in-licensed telacebec from Qurient under an exclusive license agreement, enabling the nonprofit organization to advance the compound’s development with a focus on public health impact and access. Telacebec works by targeting mycobacterial energy production, disrupting a critical pathway required for bacterial survival. Preclinical studies have demonstrated potent activity against Mycobacterium tuberculosis, as well as Mycobacterium ulcerans, the causative agent of Buruli ulcer, and Mycobacterium leprae, the causative agent of leprosy. These findings support the continued clinical development of telacebec as a potential new treatment option for diseases that disproportionately affect underserved populations worldwide. About TB Alliance TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB and adjacent mycobacterial diseases such as leprosy and Buruli ulcer. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Cystic Fibrosis Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Korea International Cooperation Agency, MedAccess, Raoul Follerau Foundation, South Korea’s Ministry of Foreign Affairs, United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP), United States Department of State, United States National Institutes for Health – National Center for Advancing Translational Sciences (NCATS), United States National Institutes for Health – National Institute of Allergy and Infectious Diseases (NIAID), and Unitaid. For more information, please visit: www.tballiance.org. About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupin.com or follow us on LinkedIn https://www-linkedin-com.sutd.idm.oclc.org/company/lupin

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent opened its new headquarters in Tampa, FL, on Monday. Earlier this year, the CDMO said it was planning to relocate its home base from Somerset, NJ. Lotus Pharmaceutical is acquiring New Alvogen, which owns Alvogen, in a deal worth around $2 billion, the company said Tuesday. Lotus will gain Alvogen’s US manufacturing facility and two production platforms for R&D and manufacturing. Fujifilm Biotechnologies opened a manufacturing site in Holly Springs, NC. The first phase was a $3.2 billion build for drug product and substance production. Other capabilities will be added in 2026, a Wednesday release said. Lonza’s subsidiary Synaffix has partnered with South Korean biotech Qurient to develop a dual-payload antibody-drug conjugate, according to a Thursday release. The ADC will use Qurient’s CDK7 inhibitor to tackle solid tumors. Thermo Fisher Scientific will provide bioreactors and other technologies to Dr. Park. The South Korean CDMO will use the equipment at its new viral vector facility, Thermo Fisher said on Wednesday. ITM Isotope Technologies will supply the radioisotope terbium-161 to TerThera, according to a Wednesday release. Lonza is partnering with Rion to provide commercial-scale manufacturing for its exosome drug products, the company announced on Tuesday.

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC. Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and mitigate payload resistance. Their therapeutic promise can potentially expand the current range of effective treatments while minimizing toxicity to healthy tissues, especially in refractory cancer cases. The collaboration aims to develop a dual-payload ADC consisting of Synaffix's exatecan-based technology and Qurient's CDK7 inhibitor, aiming to target unmet medical needs in solid tumors. Under the terms of the agreement, Qurient will gain access to Lonza's clinical-stage, site-specific ADC technology platform powered by Synaffix services including GlycoConnect® antibody conjugation, HydraSpace® polar spacer, and exatecan-based linker-payload technologies, as well as Lonza's market-leading expertise and experience in developing and manufacturing bioconjugates. Lonza will manufacture components related to its proprietary Synaffix technologies, and Qurient will perform the research, development, manufacturing and commercialization of the ADC, and manufacturing of Qurient's CDK7 inhibitor. Peter van de Sande, Head of Synaffix, said: "This licensing collaboration with Qurient signifies the versatility of our industry-leading ADC platform technology. Enabling the development of a dual-payload ADC built with Synaffix technology reflects our drive to continue pioneering innovation in the field." Kiyean Nam, CEO at Qurient, said: "Dual-payload ADCs represent the next frontier in targeted antibody therapeutics, and we look forward to advancing this novel combination of our CDK7 inhibitor and Synaffix's SYNtecan™ linker-payload. The combination of our proprietary technology with Synaffix's industry-leading platform has the potential to be applicable to a wider range of targets and antibodies, and we look forward to exploring those possibilities in the future." Notes to Editors About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its partner pipeline. Synaffix was fully acquired by Lonza in June 2023. For more information about Synaffix's ADC platform technology, please visit: About Lonza Lonza is one of the world's largest development and manufacturing organizations (CDMOs). Working across five continents, our global team of more than 19,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Our company generated sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in Half-Year 2025. Find out more at About Qurient Co., Ltd. Qurient Co., Ltd. is a public clinical-stage biotechnology company headquartered in South Korea and listed on KOSDAQ, with a mission to develop innovative medicines and targeted therapies across oncology and infectious diseases. The company's pipeline includes mocaciclib (Q901), a CDK7 inhibitor targeting transcriptionally addicted cancers; adrixetinib (Q702), an AXL/MER/CSF1R inhibitor being explored for chronic graft-versus-host disease (cGvHD) and oncology indications; and telacebec (Q203), a first-in-class antibiotic in late-stage development for Tuberculosis, Buruli ulcer and other mycobacterial diseases. Qurient combines strong translational research expertise with global partnerships to advance programs from discovery through clinical development. By strategically focusing on high-unmet-need indications such as hard-to-treat cancers, drug-resistant mycobacteria, and immune-driven diseases, Qurient positions itself at the intersection of precision oncology and infectious disease innovation. For more information, please visit . SOURCE Synaffix WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED